
ADIL
Adial Pharmaceuticals Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.520
Open
0.4706
VWAP
0.50
Vol
2.43M
Mkt Cap
8.11M
Low
0.4651
Amount
1.21M
EV/EBITDA(TTM)
--
Total Shares
4.23M
EV
5.74M
EV/OCF(TTM)
--
P/S(TTM)
--
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Show More
1 Analyst Rating

289.11% Upside
Wall Street analysts forecast ADIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADIL is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy

289.11% Upside
Current: 0.514

Low
2.00
Averages
2.00
High
2.00

289.11% Upside
Current: 0.514

Low
2.00
Averages
2.00
High
2.00
Rodman & Renshaw
Brandon Folkes
Strong Buy
Initiates
$8
2024-11-14
Reason
Rodman & Renshaw
Brandon Folkes
Price Target
$8
2024-11-14
Initiates
Strong Buy
Reason
Rodman & Renshaw initiated coverage of Adial Pharmaceuticals with a Buy rating and $8 price target. The firm believes Adial has the potential to outperform over the next 12 months, saying its AD04 is designed to reduce alcohol consumption without the need for inpatient stays. The molecule being explored, ondansetron, is widely used, well-characterized, and has shown promising data to fill a gap where other treatments for alcohol use disorder fall short, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Adial Pharmaceuticals Inc (ADIL.O) is -0.78, compared to its 5-year average forward P/E of -1.79. For a more detailed relative valuation and DCF analysis to assess Adial Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.79
Current PE
-0.78
Overvalued PE
-0.41
Undervalued PE
-3.17
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-0.76
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.86
Undervalued EV/EBITDA
-2.38
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
21509.22
Current PS
0.00
Overvalued PS
98863.25
Undervalued PS
-55844.82
Financials
Annual
Quarterly
FY2025Q1
YoY :
+22.89%
-2.27M
Operating Profit
FY2025Q1
YoY :
-65.59%
-2.23M
Net Income after Tax
FY2025Q1
YoY :
-84.47%
-0.34
EPS - Diluted
FY2025Q1
-1.59M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ADIL News & Events
Events Timeline
2025-07-16 (ET)
2025-07-16
08:36:33
Adial regains compliance with Nasdaq's Equity Listing requirement

2025-07-09 (ET)
2025-07-09
08:37:30
Adial Pharmaceuticals files PCT patent application for core assets

2025-06-25 (ET)
2025-06-25
08:39:24
Adial Pharmaceuticals secures U.S.-based manufacturing through agreements

Sign Up For More Events
Sign Up For More Events
News
3.5
07-09Yahoo FinanceAlcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck
9.0
06-26NASDAQ.COMVOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14%
9.5
06-26BenzingaWhy Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Sign Up For More News
People Also Watch

INBS
Intelligent Bio Solutions Inc
1.610
USD
-15.26%

FORD
Forward Industries Inc
10.060
USD
+4.68%

PBM
Psyence Biomedical Ltd
11.500
USD
+15.12%

LGCB
Linkage Global Inc
2.700
USD
0.00%

CHNR
China Natural Resources Inc
3.750
USD
-0.53%

DSS
DSS Inc
1.150
USD
-1.71%

GNPX
Genprex Inc
0.272
USD
-4.55%

SPRC
Scisparc Ltd
7.260
USD
-5.59%

CERO
CERo Therapeutics Holdings Inc
7.580
USD
+2.16%

GBR
New Concept Energy Inc
0.970
USD
-0.61%
FAQ

What is Adial Pharmaceuticals Inc (ADIL) stock price today?
The current price of ADIL is 0.514 USD — it has increased 7.08 % in the last trading day.

What is Adial Pharmaceuticals Inc (ADIL)'s business?

What is the price predicton of ADIL Stock?

What is Adial Pharmaceuticals Inc (ADIL)'s revenue for the last quarter?

What is Adial Pharmaceuticals Inc (ADIL)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Adial Pharmaceuticals Inc (ADIL)'s fundamentals?

How many employees does Adial Pharmaceuticals Inc (ADIL). have?
